Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first time • VYJUVEK received Orphan Drug Designation and PRIME designation from the EMA PITTSBURGH, Nov. 27, 2023 (GLOBE NEWSWIRE) -- (the "Company") KRYS, a…#deb #vyjuvek #ema #pittsburgh #krys #maa #sumakrishnan #researchdevelopment #krystalbiotech #epidermolysisbullosa
Source: Reuters: Health - Category: Consumer Health News Source Type: news